Treatment, clinical outcomes, and predictors of mortality among a national cohort of hospitalized patients with Stenotrophomonas maltophilia infection

被引:6
作者
Appaneal, H. J. [1 ,2 ,3 ,5 ]
Lopes, V. V. [1 ]
LaPlante, K. L. [1 ,2 ,3 ,4 ]
Caffrey, A. R. [1 ,2 ,3 ,6 ]
机构
[1] Providence Vet Affairs Med Ctr, Infect Dis Res Program, Providence, RI USA
[2] Providence Vet Affairs Med Ctr, Ctr Innovat Long Term Support Serv, Providence, RI USA
[3] Univ Rhode Isl, Coll Pharm, Kingston, RI USA
[4] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[5] Providence Vet Affairs Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA
[6] Univ Rhode Isl, Coll Pharm, Hlth Outcomes, 7 Greenhouse Rd,Room 265B, Kingston, RI 02881 USA
关键词
Stenotrophomonas maltophilia; Predictors; Inpatient mortality; Antibiotic treatment; Clinical outcomes; BLOOD-STREAM INFECTION; RISK-FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE; LEVOFLOXACIN; BACTEREMIA; PNEUMONIA; ONSET;
D O I
10.1016/j.puhe.2022.10.025
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: To analyze treatment, clinical outcomes, and predictors of inpatient mortality in hospitalized patients with Stenotrophomonas maltophilia infection.Study design: Retrospective cohort study.Methods: We included patients admitted to Veterans Affairs hospitals nationally with S. maltophilia cultures and treatment from 2010 to 2019. We described patient and clinical characteristics, antibiotic treatment, and clinical outcomes. Univariate and multivariable logistic regression were used to evaluate predictors of inpatient mortality.Results: We identified 3891 hospitalized patients treated for an S. maltophilia infection, of which 13.7% died during admission. The most common antibiotic agents were piperacillin/tazobactam (39.7%), sul-famethoxazole/trimethoprim (23.3%), and levofloxacin (23.2%). Combination therapy was used in 16.6% of patients. Independent predictors of inpatient mortality identified in multivariable analysis included the following: presence of current acute respiratory failure (adjusted odds ratio [aOR] 4.74, 95% confi-dence interval [CI] 3.63-6.19), shock (aOR 3.00, 95% CI 2.31-3.90), acute renal failure (aOR 2.06, 95% CI 1.64-2.60), and septicemia (aOR 1.90, 95% CI 1.49-2.42), age 65 years and older (aOR 2.05, 95% CI 1.07-3.94, reference age 18-49 years), hospital-acquired infection (aOR 1.87, 95% CI 1.48-2.37), Black (aOR 1.58, 95% CI 1.21-2.06) and other races (aOR 1.65, 95% CI 1.41-2.41, reference White), liver disease (aOR 1.51, 95% CI 1.02-2.22), and median Charlson comorbidity score or higher (aOR 1.36, 95% CI 1.08-1.71, reference less than median). Clinical outcomes were similar between patients infected with sulfamethoxazole/trimethop rim-resistant, levofloxacin-resistant, and multidrug-resistant S. maltophilia strains compared to non-resistant strains.Conclusions: In our national cohort of hospitalized patients with S. maltophilia infection, 13.7% of patients died during admission and several predictors of inpatient mortality were identified. Predictors related to the severity of infection were among the strongest identified. It is important that in severely ill patients presenting to the hospital, S. maltophilia be considered as a cause.Published by Elsevier Ltd on behalf of The Royal Society for Public Health.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 33 条
[1]   Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004 [J].
Aisenberg, G. ;
Rolston, K. V. ;
Dickey, B. F. ;
Kontoyiannis, D. P. ;
Raad, I. I. ;
Safdar, A. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (01) :13-20
[2]   National trends in the treatment of urinary tract infections among Veterans' Affairs Community Living Center residents [J].
Appaneal, Haley J. ;
Caffrey, Aisling R. ;
Lopes, Vrishali V. ;
Crnich, Christopher J. ;
Dosa, David M. ;
LaPlante, Kerry L. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2019, 40 (10) :1087-1093
[3]   Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates [J].
Bonfiglio, G ;
Cascone, C ;
Azzarelli, C ;
Cafiso, V ;
Marchetti, F ;
Stefani, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (01) :115-117
[4]   Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen [J].
Brooke, Joanna S. .
CLINICAL MICROBIOLOGY REVIEWS, 2012, 25 (01) :2-41
[5]  
Caffrey A, 1585, STENOTROPHOMONAS MAL
[6]   Stenotrophomonas maltophilia bloodstream infection: Comparison between community-onset and hospital-acquired infections [J].
Chang, Ya-Ting ;
Lin, Chun-Yu ;
Lu, Po-Liang ;
Lai, Chung-Chih ;
Chen, Tun-Chieh ;
Chen, Chi-Yu ;
Wu, Deng-Chyang ;
Wang, Tzu-Pin ;
Lin, Chiu-Mei ;
Lin, Wei-Ru ;
Chen, Yen-Hsu .
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2014, 47 (01) :28-35
[7]   Can Levofloxacin Be a Useful Alternative to Trimethoprim- Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia? [J].
Cho, Sun Young ;
Kang, Cheol-In ;
Kim, Jungok ;
Ha, Young Eun ;
Chung, Doo Ryeon ;
Lee, Nam Yong ;
Peck, Kyong Ran ;
Song, Jae-Hoon .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) :581-583
[8]   Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia [J].
del Toro, MD ;
Rodríguez-Baño, J ;
Martínez-Martínez, L ;
Pascual, A ;
Pérez-Cano, R ;
Perea, EJ ;
Muniain, MA .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (01) :4-9
[9]  
Department of Veterans Affairs, 2020, STAT GLANC
[10]   Bacteraemia due to Stenotrophomonas maltophilia:: An analysis of 45 episodes [J].
Friedman, ND ;
Korman, TM ;
Fairley, CK ;
Franklin, JC ;
Spelman, DW .
JOURNAL OF INFECTION, 2002, 45 (01) :47-53